動物医療向けモノクローナル抗体の世界市場：動物タイプ・用途・エンドユーザー・地域別の分析・競合情勢・予測 (2023-2033年)

当レポートでは、世界の動物医療向けモノクローナル抗体の市場を調査し、市場概要、主要動向、法規制環境、市場影響因子および市場機会の分析、市場規模の推移・予測、各種区分・地域別の詳細分析、競合情勢、主要企業のプロファイルなどをまとめています。

目次

エグゼクティブサマリー

調査範囲

第1章 世界の動物医療向けモノクローナル抗体市場：概要

第2章 世界の動物医療向けモノクローナル抗体市場：産業分析

• 規制要件
• 主要動向
• COVID-19の動物医療向けモノクローナル抗体市場への影響

第3章 世界の動物医療向けモノクローナル抗体市場：市場力学

• 概要
• 影響分析
• 市場促進要因
• 市場抑制要因
• 市場機会

第4章 世界の動物医療向けモノクローナル抗体市場：動物タイプ別

• 概要
• 成長シェアマトリックス
• 犬
• その他

第5章 世界の動物医療向けモノクローナル抗体市場：用途別

• 概要
• 成長シェアマトリックス
• 皮膚
• 疼痛
• その他

第6章 世界の動物医療向けモノクローナル抗体市場：エンドユーザー別

• 概要
• 成長シェアマトリックス
• 動物病院
• その他

第7章 世界の動物医療向けモノクローナル抗体市場：地域別

• 概要
• 北米
• 欧州
• アジア太平洋
• ラテンアメリカ
• 中東・アフリカ
  • 概要
  • 市場規模・予測

第8章 世界の動物医療向けモノクローナル抗体市場：競合考察・企業プロファイル

• アクティブ企業のエコシステム
• 主要な戦略と展開
  • 概要
  • 提携・協力
  • M&A
  • 事業拡大
  • 製品の発売
  • 資金調達
• 企業プロファイル
  • Merck & Co, Inc.
  • Zoetis
  • Elanco
  • Boehringer Ingelheim GmbH
  • Virbac
  • Invetx
  • Indian Immunologicals Ltd.
  • その他の企業

The report on the global monoclonal antibodies in veterinary health market provides a thorough analysis of the market, providing insights into current trends, a future impact assessment, patent filing trends, and regulatory requirements for the market. It explores the impact of key global events, identifies driving factors and challenges affecting market growth, and highlights growth opportunities.

It profiles key market players and their strategies for market dominance, including a competitive analysis. The report also examines regional segmentation, estimating market presence and performance across different geographical regions worldwide, and discusses potential investment opportunities for shareholders and investors.

This report focuses on nurturing a profound understanding of market dynamics and serves as a valuable resource for business ventures, entrepreneurs, and industries looking for detailed insights into the monoclonal antibodies in veterinary health market.

Market Segmentation:

Segmentation 1: by Application

• Dermatology
• Pain
• Others

Segmentation 2: by Animal Type

• Dog
• Others

Segmentation 3: by End User

• Veterinary Hospitals
• Others

Segmentation 3: by Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Key Questions Answered:

• What are the major driving factors, opportunities, and restraints in the global monoclonal antibodies in veterinary health market?
• How will the market evolve during the forecast period, and what are its future prospects?
• What are the key players of the market and their key developmental strategies which pose them as the key players of the market?
• How will the segments evolve during the forecast period?
• Which segments hold a prominent market share and what factors are influencing their growth in the market?

Table of Contents

Executive Summary

Scope of the Study

Research Methodology

1. Global Monoclonal Antibodies in Veterinary Health Market: Overview

• 1.1 Product Definition
• 1.2 Inclusion and Exclusion Criteria
• 1.3 Key Findings

2. Global Monoclonal Antibodies in Veterinary Health Market: Industry Analysis

• 2.1 Regulatory Requirements
• 2.2 Key Trends
• 2.3 Impact of COVID-19 on Global Monoclonal Antibodies in Veterinary Health Market

3. Global Monoclonal Antibodies in Veterinary Health Market: Market Dynamics

• 3.1 Overview
• 3.2 Impact Analysis
• 3.3 Market Drivers
• 3.4 Market Restraints
• 3.5 Market Opportunities

4. Global Monoclonal Antibodies in Veterinary Health Market (by Animal Type)

• 4.1 Overview
• 4.2 Growth-Share Matrix
• 4.3 Dog
• 4.4 Others

5. Global Monoclonal Antibodies in Veterinary Health Market (by Application)

• 5.1 Overview
• 5.2 Growth-Share Matrix
• 5.3 Dermatology
• 5.4 Pain
• 5.5 Others

6. Global Monoclonal Antibodies in Veterinary Health Market (by End User)

• 6.1 Overview
• 6.2 Growth-Share Matrix
• 6.3 Veterinary Hospitals
• 6.4 Others

7. Global Monoclonal Antibodies in Veterinary Health Market, (by Region)

• 7.1 Overview
• 7.2 North America Monoclonal Antibodies in Veterinary Health Market
  • 7.2.1 Overview
  • 7.2.2 Market Size and Forecast
    • 7.2.2.1 North America Monoclonal Antibodies in Veterinary Health Market, by Country
      • 7.2.2.1.1 U.S.
      • 7.2.2.1.2 Canada
• 7.3 Europe
  • 7.3.1 Overview
  • 7.3.2 Market Size and Forecast
    • 7.3.2.1 Europe Monoclonal Antibodies in Veterinary Health Market, by Country
      • 7.3.2.1.1 Germany
      • 7.3.2.1.2 U.K.
      • 7.3.2.1.3 France
      • 7.3.2.1.4 Italy
      • 7.3.2.1.5 Spain
      • 7.3.2.1.6 Rest of Europe
• 7.4 Asia-Pacific
  • 7.4.1 Overview
  • 7.4.2 Market Size and Forecast
    • 7.4.2.1 Asia-Pacific Monoclonal Antibodies in Veterinary Health Market, by Country
      • 7.4.2.1.1 China
      • 7.4.2.1.2 Japan
      • 7.4.2.1.3 India
      • 7.4.2.1.4 South Korea
      • 7.4.2.1.5 Australia and New Zealand
      • 7.4.2.1.6 Rest of Asia-Pacific
• 7.5 Latin America
  • 7.5.1 Overview
  • 7.5.2 Market Size and Forecast
    • 7.5.2.1 Latin America Monoclonal Antibodies in Veterinary Health Market, by Country
      • 7.5.2.1.1 Brazil
      • 7.5.2.1.2 Mexico
      • 7.5.2.1.3 Rest of Latin America
• 7.6 Middle East and Africa
  • 7.6.1 Overview
  • 7.6.2 Market Size and Forecast
    • 7.6.2.1 Middle East and Africa Monoclonal Antibodies in Veterinary Health Market, by Country
      • 7.6.2.1.1 U.A.E
      • 7.6.2.1.2 South Africa
      • 7.6.2.1.3 Rest-of-Middle East and Africa

8. Global Monoclonal Antibodies in Veterinary Health Market: Competitive Insights and Company Profiles

• 8.1 Global Monoclonal Antibodies in Veterinary Market Active Players Ecosystem
• 8.2 Key Strategies and Developments
  • 8.2.1 Overview
  • 8.2.2 Collaborations and Partnerships
  • 8.2.3 Acquisitions and Mergers
  • 8.2.4 Business Expansions
  • 8.2.5 Product Launches
  • 8.2.6 Funding
• 8.3 Company Profiles
  • 8.3.1 Merck & Co, Inc.
    • 8.3.1.1 Company Overview
    • 8.3.1.2 Product Portfolio
    • 8.3.1.3 Financials
    • 8.3.1.4 Recent Developments
    • 8.3.1.5 Analyst View
  • 8.3.2 Zoetis
  • 8.3.3 Elanco
  • 8.3.4 Boehringer Ingelheim GmbH
  • 8.3.5 Virbac
  • 8.3.6 Invetx
  • 8.3.7 Indian Immunologicals Ltd.
  • 8.3.8 Other Companies